Drug Profile
MK 3887
Alternative Names: MK-3887Latest Information Update: 21 Dec 2007
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 01 Aug 2006 Phase-I clinical trials in Diabetes mellitus in USA (unspecified route)